Document:

STOCK PURCHASE AGREEMENT

      THIS STOCK PURCHASE AGREEMENT (this "Agreement") is made as of this 31st
day of October, 2005, by and between Magna-Lab, Inc., a New York corporation
(the "Company"), and Magna Acquisition LLC (the "Investor").

      WHEREAS, the Company desires to issue and sell 30,000,000 shares (the
"Shares") of its class A common stock, $0.001 par value ("Common Stock"), to
Investor and Investor desires to purchase the Shares;

      WHEREAS, pursuant to a separate agreement, Investor has agreed to purchase
from a principal stockholder of the Company who is currently in receivership,
Noga Investments in Technologies, Ltd. ("Noga"), and Noga has agreed to sell to
Investor, all of the shares of Common Stock owned by Noga (the "Noga
Agreement");

      WHEREAS, the parties hereto desire to make certain representations,
warranties and agreements in connection with the proposed purchase and sale of
the Shares and to establish various rights and obligations in connection
therewith;

      NOW, THEREFORE, in consideration of the promises, representations,
warranties, covenants and agreements contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, each of the parties hereto, intending to be legally bound, hereby
agree as follows:

SECTION 1. PURCHASE AND SALE OF SHARES

1.1 Sale and Purchase. Upon the terms and subject to the conditions contained
herein, and in reliance on the representations and warranties set forth in
Sections 2 and 3 below, at the Closing (as defined below): Investor shall
purchase from the Company, and the Company shall issue and sell to Investor
thirty million (30,000,000) shares of Common Stock at a purchase price of
$0.006333 per share for an aggregate purchase price of $190,000 (the "Purchase
Price").

1.2 Consideration. At Closing, Investor shall deliver to the Company by wire
transfer of immediately available U.S. funds the amount of $190,000 to the
account or accounts specified by the Company, and the Company shall direct its
transfer agent to issue the Shares to the Investor.

1.3 Closing. The closing of the purchase and sale of the Shares (the "Closing")
shall take place effective on the date hereof (the "Closing Date") by mail or at
such place as shall be mutually agreed to by the parties hereto.

1.4 Closing Condition. On or before the Closing, the Company shall have
delivered to the Investor a copy of the Settlement and Release Agreement
attached hereto fully executed by each of the parties thereto, under which,
among other things, the Company agrees to issue to Management and former
management (as defined therein) 2,973,923 shares of Common Stock of the Company
in exchange for (i) full settlement of accrued and unpaid compensation owing to
Management and former management for the period from September 1, 2002 through
January 15, 2003, and (ii) cancellation of options to purchase up to 2,325,000
shares of Common Stock of the Company held by some of Management and former
management.

                                       1
<PAGE>

1.5 Post-Closing Covenant. On or promptly following the Closing, the Company
shall issue and deliver to Noga a written release and waiver of any and all
claims, demands or causes or action whatsoever against Noga relating to the
shares of Common Stock Noga purchased from the Company, which release and waiver
is contemplated by, and a condition to closing of, the Noga Agreement.

SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY

In order to induce the Investor to enter into this Agreement, the Company
represents and warrants to Investor:

2.1 Organization and Corporate Power. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of
New York. The Company has all required corporate power and authority to carry on
its business as presently conducted, to enter into and perform this Agreement
and each agreement, document and instrument to be executed and delivered by or
on behalf of the Company pursuant to or as contemplated by this Agreement and to
carry out the transactions contemplated hereby and thereby, including the
issuance and sale of the Shares. Copies of the Articles of Incorporation and
Bylaws of the Company have been provided to the Investor and are complete and
correct.

2.2 Capitalization. The authorized and issued capital stock of the Company is as
set forth in the Offering Documents (as defined below). The shares have been
duly authorized and upon issuance pursuant to the terms of this Agreement will
be validly issued, fully paid and nonassessable and not subject to any
preemptive rights of the shareholders of the Company. The Company presently has
no commitments to issue additional shares of capital stock, except for: (i)
300,000 shares of Common Stock reserved for issuance pursuant to outstanding
stock options exercisable at $.25 per share and expiring December 31, 2005 and
(ii) 1,875,000 shares of Common Stock reserved for issuance pursuant to
outstanding stock options exercisable at $0.49 per share and expiring in
increments of 625,000 on each of January 31, 2006, August 31, 2006 and January
31, 2007. In addition, the Company has entered into transactions pursuant to
which it will issue or commit to issue: (i) 2,973,923 shares of Common Stock to
management and former management pursuant to the Settlement and Release
Agreement referred to in Section 1.4 hereof and (ii) 1,500,000 shares of Common
Stock to Kenneth C. Riscica as additional compensation for his continued efforts
on behalf of the Company. Further, the Company has reserved 9,000,000 shares of
Common Stock for issuance to directors and management in the event that their
efforts result in Board approval of a merger or financing transaction.

                                       2
<PAGE>

2.3 Material Agreements; No Defaults. Except as set forth in the SEC Documents
(as defined below), the Company is not a party to any contract or agreement that
involves material payments of cash, stock or other property to or from the
Company. The Company is not in violation of or default under any provision of
any such contract or agreement to which it is a party, except as would not have
a material adverse effect on the business, financial condition or results of
operations of the Company taken as a whole.

2.4 Compliance with Law. The Company is not in default with respect to any
judgment, order, writ, injunction, decree or award, and the Company is not in
violation of, and the business of the Company is presently being conducted so as
to comply in all material respects with, applicable Federal, state and local
governmental laws and regulations, all to the extent necessary to avoid any
material adverse effect on the business, properties or financial condition of
the Company, except as disclosed in the Offering Documents.

2.5 SEC Documents; Financial Statements. The Common Stock is registered pursuant
to Section 12(g) of the Securities Exchange Act of 1934 (the "Exchange Act") and
the Company is required to file reports and statements with the Securities and
Exchange Commission (the "SEC") pursuant to the requirements of the Exchange
Act. All such reports and statements filed by the Company with the SEC during
the current fiscal year and for the three prior fiscal years are referred to
herein as the "SEC Documents". As of their respective dates, the SEC Documents
complied in all material respects with the requirements of the Exchange Act and
the rules and regulations of the SEC promulgated thereunder applicable to the
SEC Documents. As of their respective dates, the financial statements of the
Company and its subsidiary included in the SEC Documents complied as to form in
all material respects with applicable accounting requirements and the published
rules and regulations of the SEC. Such financial statements have been prepared
in accordance with generally accepted accounting principles applied on a
consistent basis during the periods involved (except (a) as may be otherwise
indicated in such financial statements or the notes thereto, or (b) in the case
of unaudited interim statements, to the extent they may exclude footnotes or may
be condensed or summary statements) and fairly present the financial position of
the Company and its subsidiary as of the dates thereof and the results of its
operations and cash flows for the periods then ended (subject, in the case of
unaudited statements, to normal year-end audit adjustments).

2.6 Authorization and Non-Contravention. The execution, delivery and performance
by the Company of this Agreement and each agreement, document and instrument to
be executed and delivered by or on behalf of the Company pursuant to or as
contemplated by this Agreement and the issuance and sale of the Shares, have
been duly authorized by all necessary corporate action of the Company. This
Agreement and each agreement, document and instrument to be executed and
delivered by or on behalf of the Company pursuant to or as contemplated by this
Agreement constitutes a valid and binding obligation of the Company, enforceable
in accordance with its terms. The execution and delivery by the Company of this
Agreement and each agreement, document and instrument to be executed and
delivered by or on behalf of the Company pursuant to or as contemplated by this
Agreement and the performance by the Company of the transactions contemplated
hereby and thereby, including the issuance and delivery of the Shares, do not
and will not: (A) violate, conflict with or result in a default (whether after
the giving of notice, lapse of time or both) under any material contract or

                                       3
<PAGE>

obligation to which the Company is a party or by which it or its assets are
bound and which have not been waived, or any provision of the articles of
incorporation or bylaws of the Company; (B) to the Company's knowledge, violate
or result in a violation of, or constitute a default under, any provision of any
material law, regulation or rule, or any order of, or any restriction imposed
by, any court or governmental agency applicable to the Company; (C) require from
the Company any notice to, declaration or filing with, or consent or approval of
any governmental authority or third party other than as may be required to
secure an exemption from qualification of the offer and sale of the Shares under
the Securities Act of 1933, as amended (the "Securities Act"); or (D) accelerate
any obligation under, or give rise to a right of termination of, any material
agreement, permit, license or authorization to which the Company is a party or
by which the Company is bound.

2.7 Securities Laws. In reliance on the investment representations contained in
Section 3, the offer, issuance, sale and delivery of the Shares, as provided in
this agreement, are exempt from the registration requirements of the Securities
Act.

2.8 No Other Representations. Other than as set forth in this Section 2, the
Company makes no other representations and warranties to Investor, written or
oral, including without limitation, any representation with respect to the
valuation of the Company.

SECTION 3. REPRESENTATIONS AND WARRANTIES OF INVESTOR

In order to induce the Company to enter into this Agreement, the Investor
represents and warrants to the Company:

3.1. Investment Intention. Investor is purchasing the Shares for its own
account, for investment purposes and not with a view to the distribution
thereof. Investor will not, directly or indirectly, offer, transfer, sell,
assign, pledge, hypothecate or otherwise dispose of any of the Shares, except in
compliance with the Securities Act.

3.2. Accredited Investor. Investor is an "Accredited Investor" (as that term is
defined in Rule 501 of Regulation D under the Securities Act) and by reason of
its business and financial experience, it has such knowledge, sophistication and
experience in business and financial matters as to be capable of evaluating the
merits and risks of the prospective investment and making an informed investment
decision with respect thereto; is able to bear the economic risk of such
investment and is able to afford a complete loss of such investment; and has
made an independent investigation of the Company and relied upon its own due
diligence, valuation analysis and other analyses in determining to purchase the
Shares.

3.3 Offering Documents. The Investor acknowledges receipt and careful review of
the Company's Annual Report on Form 10-KSB for the fiscal year ended February
28, 2005 and the Company's Quarterly Reports on Form 10-QSB for the three months
ended May 31, 2005 and for the three and six months ended August 31, 2005
(collectively, the "Offering Documents"). The Investor hereby represents that it

                                       4
<PAGE>

has been furnished by the Company during the course of this transaction with all
information regarding the Company which the Investor had requested or desired to
know, that all documents which could be reasonably provided have been made
available for the Investor's inspection and review, and that the Investor has
been afforded the opportunity to ask questions of and receive answers from duly
authorized officers or other representatives of the Company concerning this
transaction, and any additional information which the Investor had requested.
The Investor hereby represents that, except as set forth in this Agreement and
the Offering Documents, no representations or warranties have been made to the
Investor by the Company or any agent, employee or affiliate of the Company and
in entering into this transaction, the Investor is not relying on any
information, other than that contained in this Agreement and the Offering
Documents and the results of independent investigation by the Investor.

3.4. Shares Not Registered. Investor acknowledge that the Shares have not been
registered under the Securities Act or the securities laws of any state or other
jurisdiction and cannot be disposed of unless the Shares are subsequently
registered under the Securities Act and any applicable state laws or an
exemption from such registration is available. Investor understands that there
is a very limited public market for the Shares and that it must bear the
economic risk of investment in the Company for an indefinite period of time.

3.5. Legend. Investor acknowledges and agrees that the following legend shall be
placed on each certificate evidencing the Shares:

THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND
EXCHANGE COMMISSION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, HYPOTHECATED OR
OTHERWISE ASSIGNED EXCEPT (1) PURSUANT TO A REGISTRATION STATEMENT WITH RESPECT
TO SUCH SECURITIES WHICH IS EFFECTIVE UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT") OR (2) PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT, PROVIDED THAT AN OPINION OF COUNSEL TO SUCH EFFECT IS PROVIDED TO
THE COMPANY IN CONNECTION THEREWITH.

SECTION 4. GENERAL

4.1 Governing Law. This Agreement shall be deemed to be a contract made under,
and shall be construed in accordance with, the laws of the State of New York,
without giving effect to conflict of laws principles thereof.

4.2 Any controversy or claim arising out of, or relating to, this Agreement, or
its breach, shall be settled by arbitration in accordance with the then
governing rules of the American Arbitration Association. If such organization
ceases to exist, the arbitration shall be conducted by its successor, or by a
similar arbitration organization, at the time a demand for arbitration is made.

                                       5
<PAGE>

Judgment upon the award tendered may be entered and enforced in any court of
competent jurisdiction. In the event of an arbitration, the prevailing party
shall be entitled to recover from the other party its own expenses for the
arbitrator's fee, reasonable legal fees, expert testimony, costs, and expenses
incurred in connection with any contest or dispute with respect to this
Agreement; provided, however, that such fees, costs, and expenses shall only be
paid in the event the arbitrator finds that the non-prevailing party lacked a
good faith basis for the dispute or contest. Other arbitration costs, including
fees for records or transcripts, shall be borne equally by the parties.
Notwithstanding anything herein to the contrary, the Company may seek injunctive
or other equitable relief in a court of competent jurisdiction prior to, or
while the dispute is pending in, an arbitration proceeding.

4.3 Counterparts. This Agreement may be executed simultaneously in any number of
counterparts, each of which when so executed and delivered shall be taken to be
an original, but such counterparts shall together constitute but one and the
same instrument.

4.4 Notices and Demands. Any notice or demand which is required or provided to
be given under this Agreement shall be deemed to have been sufficiently given
and received for all purposes when delivered by hand, facsimile, or two (2) days
after being sent by overnight delivery providing receipt of delivery, to the
following addresses:

      if to the Company: Magna-Lab, Inc.
                         6800 Jericho Turnpike - Suite 120W
                         Syosset, NY 11791

                   Attn: Lawrence A. Minkoff, Ph.D., Chief Executive Officer
                    Fax: 516 393 5819

         if to Investor: Magna Acquisition LLC
                         8000 Towers Crescent Drive
                         Suite 1070
                         Vienna, Virginia 22182
                         Joel S. Kanter            Fax: (703) 448-7751

4.5 Successors and Assigns; Assignability. Neither this Agreement nor any right,
remedy, obligation or liability arising hereunder or by reason hereof shall be
assignable by Investor without the prior written consent of the Company. All
covenants contained herein shall bind and inure to the benefit of the parties
hereto and their respective successors and assigns.

4.6 Each party shall bear its own costs and expenses in connection with this
Agreement; provided, however, that the Company shall be responsible for the
reasonable legal fees and expenses of Investor's counsel, Barack Ferrazzano
Kirshbaum Perlman & Nagelberg LLP, incurred through the date hereof in
connection this Agreement and the Noga Agreement, not to exceed an aggregate of
$43,200.

                                       6
<PAGE>

4.7. Further Assurances. The parties agree: (a) to furnish upon request to each
other such further information; (b) to execute and deliver to each other such
other documents; and (c) to do such other acts and things, all as the other
party may reasonably request for the purpose of carrying out the intent of this
Agreement.

4.8 Integration. This Agreement, including the exhibits, documents and
instruments referred to herein or therein, constitutes the entire agreement, and
supersedes all other prior agreements and understandings, both written and oral,
among the parties with respect to the subject matter hereof.

                            [Signature Page Follows]

                                       7
<PAGE>

      IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed and delivered by their proper and duly authorized officers as of the
day and year first above written.

                              COMPANY:

                              MAGNA-LAB INC.
                              By:

                              /s/ Lawrence A. Minkoff
                              -----------------------
                              Name: Lawrence A. Minkoff, Ph.D.
                              Title: Chief Executive Officer

                              INVESTOR:

                              MAGNA ACQUISITION LLC
                              By:

                              /s/ Joel S. Kanter
                              -----------------------
                              Name: Joel S. Kanter
                              Title: President

                                       8SETTLEMENT AND RELEASE AGREEMENT

      THIS AGREEMENT is entered into by and among Lawrence A. Minkoff, Kenneth
C. Riscica, individually and on behalf of Riscica Associates, Inc., Jerome M.
Feldman, Joel S. Kanter, Jonathan Adereth, Seymour Kessler, Daniel M. Mulvena
and John R. Geisel (collectively "Management and former management") and
Magna-Lab Inc. ("Magna-Lab") as of the date on which this Agreement is accepted
by Magna-Lab.

      WHEREAS, Management and former management are owed an aggregate of
$113,112 in compensation earned but not paid during the period from September 1,
2002 through January 15, 2003 ("deferred compensation") as indicated on the
enclosed Exhibit 1; and

      WHEREAS, certain of the Management and former management hold outstanding
options to purchase an aggregate of 4,825,000 shares of common stock of
Magna-Lab Inc. ("stock options") as indicated on Exhibit 2; and

      WHEREAS, Magna-Lab Inc. does not currently have the means to pay the
deferred compensation; and

      WHEREAS, both Management and former management and Magna-Lab. believe that
it is in their mutual interest that this liability and these stock options
(other than those options to purchase 2,500,000 shares at $0.49 held by Jonathan
Adereth and expiring 625,000 on each of August 31, 2005, January 31, 2006,
625,000, August 31, 2006 and 625,000 on January 31, 2007 which shall remain
outstanding according to their terms) be resolved at this time; and

      WHEREAS, Management and former management have each agreed to release
Magna-Lab from all of its obligations to Management and former management
associated with the deferred compensation and, except for Mr. Adereth, stock
options subject to the terms and conditions set forth in this Agreement.

      NOW THEREFORE, IN CONSIDERATION OF the mutual promises and covenants
contained herein and for other good and valuable consideration, receipt and
legal sufficiency of which is hereby acknowledged, the parties hereby agree as
follows:

1.    Promptly following the date of this Agreement, Magna-Lab will issue and
      deliver to each member of Management and former management a certificate
      representing class A common shares of Magna-Lab common stock in the
      denominations set forth beside their respective names on the signature
      page hereof. In connection with the issuance of the shares, each member of
      Management and former management makes the investment and other
      representations set forth on Exhibit 3 hereto.

2.    Subject to receipt of their respective share certificates, each member of
      Management and former management hereby individually (i) releases and
      forever discharges Magna-Lab and its respective subsidiary and their
      respective officers, directors, affiliates, shareholders, agents,
      employees, representatives, successors and assigns, from any and all
      claims, defenses, demands, rights of setoff or recoupment, suits,
      lawsuits, liabilities, damages, actions, causes of action or complaints of
      whatever nature or kind, formal or informal, known or unknown, in law or
      at equity, in tort or contract ("Claims") relating to the deferred
      compensation to which each is entitled as set forth on Exhibit 1 and (ii)
      except for Mr. Adereth, cancels all stock options to which each is
      entitled as set forth on Exhibit 2.

<PAGE>

3.    Promptly following the date of this Agreement and in order to
      administratively effectuate the cancellation of stock options referred to
      above, each member of Management and former management, other than Mr.
      Adereth, will tender to Magna-Lab for cancellation each original stock
      option agreement, if any.

4.    Each member of Management and former management represents and warrants to
      Magna-Lab that the deferred compensation listed on Exhibit 1 and the stock
      options listed on Exhibit 2, if any, opposite their respective names
      constitutes the full amount of compensation owing by Magna-Lab to such
      persons, except for any current services which have been billed and
      recorded by the Company, and the full number of stock options, if any,
      owned or owing to such persons.

5.    The parties agree that they are entering into this Agreement as a
      compromise and to avoid the cost and expense of any dispute or litigation.
      By entering into this agreement, neither party admits wrongdoing or any
      liability whatsoever.

6.    This Agreement shall be of no force or effect unless and until accepted by
      Magna-Lab, which acceptance shall not be valid unless obtained on or
      before September 30, 2005.

7.    This Agreement embodies the full and complete understanding and agreement
      between the parties hereto with respect to the matters involved herein,
      and supercedes any previous negotiations or agreements between the parties
      with respect to such matters. This Agreement was not entered into in
      reliance upon any statement or representation by either party other than
      those set forth herein. If one or more provisions of this Agreement are
      held to be unenforceable under applicable law, such provisions(s) shall be
      excluded from this Agreement and the balance of the Agreement shall be
      interpreted as if such provision(s) were so excluded (but in a manner that
      most closely effects the intent of the parties as of the date of this
      Agreement) and the modified agreement shall be enforceable in accordance
      with its remaining terms. No amendment or modification of this Agreement
      shall be effective unless executed in writing by the parties hereto.

8.    The parties state that it is their intention that this Agreement be given,
      and remain in effect, as a full and complete release of the Claims
      described herein, notwithstanding the discovery or existence of any
      additional Claims or facts not now known or suspected which may exist in
      any party's favor, which if known might have materially affected this
      Agreement.

9.    This Agreement shall be binding and inure to the benefit of each of the
      parties, and to each of their attorneys, agents, directors, officers,
      employees, heirs, executors, administrators, legal successors and assigns,
      and any other person claiming by and through them.

10.   The parties acknowledge that they are authorized and competent to execute
      this Agreement, and that before executing it, each has read this document,
      discussed and reviewed it with their counsel, and that each part fully
      understands each provision contained herein.

<PAGE>

11.   This Agreement may be executed in two or more counterparts each of which
      shall be considered an original, but all of which together shall
      constitute the same agreement.

12.   If any action, suit or proceeding is brought by a party hereto with
      respect to any controversy, claim or other matter arising out of or
      relating to this Agreement, or the breach thereof, all costs and expenses
      of such action, suit or proceeding, including reasonable attorney's fees
      and expenses, shall be borne by each party separately.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of
the day and year set forth below and do each hereby warrant and represent that
their respective signatories whose signature appears below have been and are on
the date of this Agreement duly authorized by all necessary and appropriate
action to execute this Agreement.

By: /s/ Lawrence A Minkoff                   By: /s/ Kenneth C. Riscica
    -------------------------------              -------------------------------
Name: Lawrence A. Minkoff (764,068 shares)   Name: Kenneth C. Riscica,
                                                   individually and on behalf of
                                                   Riscica Associates Inc.
                                                   (610,212 shares)

By: /s/ Jerome Feldman                       By: /s/ Joel Kanter
    -------------------------------              -------------------------------
Name: Jerome Feldman (157,682 shares)        Name: Joel Kanter (142,035 shares)

By: /s/Jonathan Adereth                      By: /s/ Seymour Kessler
    -------------------------------              -------------------------------
Name: Jonathan Adereth (208,620 shares)      Name: Seymour Kessler
                                                   (142,035 shares)

By: /s/ Daniel M. Mulvena                    By: /s/ John R. Geisel
    -------------------------------              -------------------------------
Name: Daniel M.Mulvena (166,948 shares)      Name: John R. Geisel
                                                   (782,323 shares)

ACCEPTED:

MAGNA-LAB INC.

By: /s/ Kenneth C. Riscica
    -------------------------------
Name: Kenneth C. Riscica
Title: Treasurer and Secretary
Date: as of September 29, 2005

By: /s/ Lawrence A. Minkoff
    -------------------------------
Name: Lawrence A. Minkoff
Title: President
Date: as of September 29, 2005

<PAGE>

                                   EXHIBIT #1
                              Deferred Compensation
                        Management and former management

            Geisel                                             $ 30,000
            Minkoff                                            $ 29,300
            Riscica                                            $ 23,400
            Adereth                                            $  8,000
            Mulvena                                            $  6,162
            Feldman                                            $  5,417
            Kanter                                             $  5,417
            Kessler                                            $  5,417
                                                               --------
                                                               $113,112
                                                               --------

                                   EXHIBIT #2
                            Outstanding Stock Options
                        Management and former management

                        Options                                  Strike
                          O/S               Term                 Price
                        -------             ----                 ------

            Geisel            0       expired 2004                    0
            Minkoff           0       expired 2003 & 2004             0
            Riscica           0       expired 2003 & 2004             0
            Adereth   2,500,000       expires in 2005 & 2006      $0.49
            Mulvena     600,000       expires 2005, 2006, 2007    $0.22
            Feldman   1,575,000       expires 2005 & 2006         $0.28
            Kanter       75,000       expires 1/1/2006            $0.25
            Kessler      75,000       expires 1/1/2006            $0.25
                      ---------
                      4,825,000
                      ---------

<PAGE>

                                    EXHIBIT 3
                           Investment Representations

(a)   Each of Lawrence A. Minkoff, Kenneth C. Riscica, Jerome M. Feldman, Joel
      S. Kanter, Jonathan Adereth, Seymour Kessler, Daniel M. Mulvena and John
      R. Geisel (collectively "Management and former management") has been given
      the opportunity to ask questions of, and receive answers from, Magna-Lab
      Inc. ("Magna") concerning the business of Magna and to obtain such
      additional written information, to the extent Magna possesses such
      information or can acquire it without unreasonable effort or expense,
      necessary to verify the accuracy of same as Magna desires in order to
      evaluate the investment. Each member of Management and former management
      has also been given the opportunity to review Magna's public filings with
      the Securities and Exchange Commission. Each member of Management and
      former management acknowledges that they have received no representations
      or warranties from Magna or its employees or agents in making this
      investment decision.

(b)   Each member of Management and former management is aware that its
      investment in Magna is speculative, involving a high degree of risk and
      that there is no guarantee that they will realize any gain from the
      investment, and that they could lose the total amount of their investment.

(c)   Each member of Management and former management is purchasing the class A
      common stock of Magna-Lab Inc. ("Shares") for his own account, with no
      present intention of dividing or allowing others to participate in this
      investment or of reselling or otherwise participating, directly, in a
      distribution of the Shares, and shall not make any sale, transfer, or
      pledge thereof without registration under the Securities Act of 1933 and
      any applicable securities laws of any state or unless an examination from
      registration is available under those laws.

(d)   Each member of Management and former management represents that he is an
      "Accredited Investor" as defined in Rule 501(a) of Regulation D
      promulgated under the Securities Act of 1933.

(e)   Each member of Management and former management has such knowledge and
      experience in financial and business matters as to be capable of
      evaluating the merits and risks of an investment in the Shares.

(f)   Each member of Management and former management acknowledges that the
      certificate for the Shares will contain a legend substantially as follows:

      THE SECURITIES WHICH ARE REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
      REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE
      SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE DISPOSED OF UNTIL A
      REGISTRATION STATEMENT WITH RESPECT THERETO IS DECLARED EFFECTIVE UNDER
      SUCH ACT, OR THE COMPANY RECEIVES AN OPINION OF COUNSEL FOR THE COMPANY
      THAT AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT IS
      AVAILABLE.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]